Gene Solutions releases the new logo and brand identity

In celebration of the 6th birthday, Jan 23, 2017 – Jan 23, 2023, Gene Solutions renews its logo from December 12, 2022.

Source: Gene Solutions – Gene Solutions officially releases new brand identity on 12/12/2022. 

The new logo features 23 pairs of chromosomes in a gene. Standing in the logo’s center is an aesthetic image of a sun, a metaphor for a hopeful and new future when people are more equipped with genetic knowledge, understand how inherited factors and environment influence humans’ well-being, and proactively choose a healthier lifestyle to prevent diseases.

Throughout the past 6 years, we have put all of our dedication and devotion in what we do and are proud to be at the frontline of genetic research, development, and applying affordable advanced gene solutions to thousands of pregnant women and cancer patients.

Gene Solutions is a place where Science meets Humanity. We gradually contribute to improve life quality standards and establish the foundation for future healthcare development.

Genetic testing is now more accessible to Vietnamese people. Data derived from cell-free DNA is significantly effective in improving diagnostic tests for diseases and common types of mutations, paving the way for the development of many clinical applications in the future. Until April 2022, Gene Solutions has been conducting a total of more than 500,000+ tests, including 400,000+ tests for pregnant women, 20,000+ diagnostic tests for pediatric patients, 30,000+ tests for inherited cancer screening, and most recently, 10,000+ tests of early cancer screening using the technology that can detect circulating tumor DNA – ctDNA in the blood stream.

Throughout the past 6 years, we have put all of our dedication and devotion in what we do and are proud to be at the frontline of genetic research, development, and applying affordable advanced gene solutions to thousands of pregnant women and cancer patients.

Next Generation Sequencing technology is also Gene Solutions’ strengths and has been widely applied in our tests thanks to its precision and safety for patients or customers. We also work with 2,000+ oncology hospitals and prestigious clinics, 2,500+ partner doctors across Vietnam to provide a holistic care for our customer: before, during and after the tests.


Source: Gene Solutions –Certified for international standards ISO 15189: 2012 and EMQN – UK, the laboratories are operated with a single protocol to help speed up the testing process.

Gene Solutions is working toward providing an ecosystem of genetic testing for proactive healthcare. Our NIPT (noninvasive prenatal testing) ecosystem of tests are developed “For the confidence of every mom”, and same for the ecosystem of oncology products, we aim to create “A future without fear of cancer”. Starting from mid-2022, Gene Solutions has established branch offices in Thailand, Singapore, Indonesia and Philippines in order to expand to Southeast Asian region to serve a wider population with similar genomes.

The change of our brand identity and logo is not simply an act of branding, but also a comprehensive transformation of the whole business. Such transformation would include the standardizing laboratory procedures to “single-flow protocol” in order to accelerate the sequencing process, analyze more mutations, and gene types and maximize the capacity of our internationally certified laboratories.


Source: Gene Solutions – Gene Solutions utilizes 10+ state-of-the-art Next Generation Sequencing instruments from Illumina and MGI.

Social responsibility, humanity, and compassion are always at the heart of every Gene Solutions‘ developments. In the future, Gene Solutions continues to put more efforts to make our state-of-the-art technology more accessible and affordable to the needy.

Inspired from the new brand identity, Gene Solutions would strive to have more breakthroughs, become a trusted partner of scientists, medical practitioners, genetic experts, and continue to live our mission as applying pioneering NGS-based genetic testing in disease prevention, diagnosis, treatment monitoring, because we believe that everyone deserves a better healthcare that are both advanced and affordable.

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More